(CIDRAP News) SIGA Technologies Inc. announced this week that it has been awarded a $55 million federal contract to develop a new formulation of its experimental smallpox drug, called ST-246, and carry out related efforts.
The company, based in New York City, said it had previously received a $16.5 million contract to develop the drug, described as "a potent, non-toxic inhibitor of orthopoxviruses."